Standard BioTools Inc.
NASDAQ:LABMedical - Devices
+$0.03 today
- Market cap
- $225.03M
- Beta
- 1.38
- P/E (TTM)
- -3.5
- EPS (TTM)
- -$0.24
Volume 0.70M
Average 2.91M
LAB Total Current Liabilities
All obligations due within one year.
Standard BioTools Inc.NASDAQ: LAB
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities falls 25.0% from a year ago
Total current liabilities stood at $42.2M at the end of Q1 FY2026, down 25.0% from a year earlier and down 61.0% from the prior quarter. Over 3 fiscal years it compounded at +35.6% a year.
Context
- Total current liabilities amounted to 6.6% of total assets at the end of Q1 FY2026, down 3.1 pp from a year earlier.
- Total current liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether total current liabilities keeps falling in the next quarterly balance sheet after a -25.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 108.31M USD
- Year-over-year change
- +64.4%
- 4-year CAGR
- +21.6%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 108.31M | +64.4% |
| FY2024 | 2024-12-31 | 65.89M | -39.7% |
| FY2023 | 2023-12-31 | 109.33M | +151.7% |
| FY2022 | 2022-12-31 | 43.44M | -12.4% |
| FY2021 | 2021-12-31 | 49.57M | — |
Total Current Liabilities vs competitors
How LAB compares with its peers on the latest reported figures
- Peers report in different currencies, so total current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -25.0% is the lowest of 11, against a peer median of +18.3%.
- Total current liabilities amounts to 6.6% of total assets for LAB, versus a peer median of 18.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | CN¥857.29M CNY | +46.0% | +13.4% | 32.3% | |
| Apr 2026 | $195.3M USD | +15.7% | +2.6% | 17.9% | |
| Mar 2026 | $148.1M USD | -15.3% | -19.2% | 22.8% | |
| Mar 2026 | $131.2M USD | -4.4% | -4.7% | 12.5% | |
| Mar 2026 | $80.94M USD | +19.6% | +16.6% | 18.0% | |
| Mar 2026 | $67.63M USD | +17.0% | -5.0% | 23.2% | |
| Mar 2026 | $47.18M USD | +25.8% | +14.4% | 9.4% | |
| Mar 2026 | $42.2M USD | -25.0% | +35.6% | 6.6% | |
| Mar 2026 | $35.15M USD | +28.5% | +18.8% | 8.7% | |
| Mar 2026 | $34.49M USD | +4.0% | +0.4% | 18.7% | |
CBLLCeriBell, Inc. | Mar 2026 | $16.18M USD | +36.8% | +24.8% | 9.1% |
| Peer median (excluding LAB) | — | +18.3% | +8.0% | 18.0% | |
Competitors are the stored peer set for LAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 28.45M | 81.31M | 51.7M | 166.73M | 118.21M |
| Short-term Investments | 0 | 84.48M | 63.19M | 126.15M | 69.36M |
| Net Receivables | 18.32M | 17.28M | 19.66M | 33.61M | 13.43M |
| Inventory | 20.83M | 21.47M | 20.53M | 40.74M | 19.98M |
| Other Current Assets | 16K | 4.28M | 3.13M | 8.66M | 233.28M |
| Total Current Assets | 72.07M | 208.82M | 158.22M | 375.88M | 454.26M |
| Property, Plant & Equipment (Net) | 65.15M | 59.54M | 54.85M | 71.38M | 46.01M |
| Goodwill | 106.38M | 106.25M | 106.32M | 111.3M | 0 |
| Intangible Assets | 27.93M | 12.6M | 1.4M | 28.95M | 0 |
| Long-term Investments | 1M | 0 | 0 | 0 | 25.7M |
| Tax Assets | (1M) | 0 | 0 | 0 | 38.63M |
| Other Non-current Assets | 3.69M | 3.11M | 2.29M | 24.83M | 3.15M |
| Total Non-current Assets | 203.15M | 181.5M | 164.85M | 236.46M | 113.49M |
| Total Assets | 275.21M | 390.31M | 323.07M | 612.34M | 567.75M |
| Account Payables | 10.6M | 7.91M | 9.24M | 12.28M | 5.41M |
| Short-term Debt | 6.84M | 2.08M | 59.53M | 0 | 5.49M |
| Tax Payables | 1.41M | 1.17M | 825K | 1.58M | 0 |
| Deferred Revenue | 15.48M | 14.44M | 16.74M | 18.59M | 38.95M |
| Other Current Liabilities | 8.67M | 3.97M | 12.05M | 14.71M | 58.46M |
| Total Current Liabilities | 49.57M | 43.44M | 109.33M | 65.89M | 108.31M |
| Long-term Debt | 64.21M | 62.81M | 3.98M | 299K | 299K |
| Deferred Tax Liabilities | 4.33M | 1.06M | 841K | 1.08M | 810K |
| Deferred Revenue (Non-current) | 24.08M | 18.18M | 14.28M | 39.92M | 7.79M |
| Other Non-current Liabilities | 882K | 312.21M | 312.32M | 6.96M | 1.21M |
| Total Non-current Liabilities | 131.05M | 428.33M | 361.79M | 74.73M | 35.15M |
| Total Liabilities | 180.62M | 471.78M | 471.12M | 140.62M | 143.46M |
| Common Stock | 77K | 80K | 83K | 396K | 404K |
| Retained Earnings | (736M) | (926.1M) | (1B) | (1.19B) | (1.26B) |
| Accumulated OCI | (907K) | (1.9M) | (2.22M) | 1.23M | (1.49M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 94.6M | (81.47M) | (148.05M) | 471.72M | 424.29M |
| Total Debt | 111.65M | 102.66M | 98.21M | 33M | 30.83M |
| Net Debt | 83.2M | 21.35M | 46.51M | (133.73M) | (87.39M) |
Standard BioTools Inc.
NASDAQ:LAB
Intrinsic Alpha fair value
Locked
Current Price
$0.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.